JHL Biotech Announces China Approves Clinical Trial Rituximab Biosimilar to Treat Non-Hodgkin Lymphoma
HSINCHU and WUHAN, July 6, 2018 /PRNewswire/ — JHL Biotech announced today that the Center for Drug Evaluation (CDE), State Drug Administration of China (SDA) has approved JHL’s Phase I…